Application of Next Generation Sequencing in Laboratory Medicine

키워드

참고문헌 (233)

1. Goodwin S, "Coming of age: ten years of next-generation sequencing technologies", Nat Rev Genet, 17, pp.333~351 (2016)
2. Schwarze K, "The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom", Genet Med, 22, pp.85~94 (2020)
3. Lalonde E, "Clinical impact of genomic information in pediatric leukemia", Front Pediatr, 5, pp.263~ (2017)
4. Gutowska-Ding MW, "One byte at a time: evidencing the quality of clinical service next-generation sequencing for germline and somatic variants", Eur J Hum Genet, 28, pp.202~212 (2020)
5. Gwinn M, "Next-generation sequencing of infectious pathogens", JAMA, 321, pp.893~894 (2019)
6. Hoadley KA, "Cell-oforigin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer", Cell, 173, pp.291~304.e6 (2018)
7. Luh F, "FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine", NPJ Genom Med, 3, pp.28~ (2018)
8. Allegretti M, "Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations", J Exp Clin Cancer Res, 37, pp.47~ (2018)
9. Yuan M, "The emerging treatment landscape of targeted therapy in non-small-cell lung cancer", Signal Transduct Target Ther, 4, pp.61~ (2019)
10. Mardis ER, "A decade’s perspective on DNA sequencing technology", Nature, 470, pp.198~ (2011)
11. Mardis ER, "DNA sequencing technologies: 2006–2016", Nature Protoc, 12, pp.213~ (2016)
12. Shendure J, "Next-generation DNA sequencing", Nature Biotechnol, 26, pp.1135~ (2008)
13. Glenn TC, "Field guide to next-generation DNA sequencers", Molecular Ecol Resour, 11, pp.759~769 (2011)
14. Sanger F, "Use of DNA polymerase I primed by a synthetic oligonucleotide to determine a nucleotide sequence in phage f1 DNA", Proc Natl Acad Sci U S A, 70, pp.1209~1213 (1973)
15. Sanger F, "Determination of a nucleotide sequence in bacteriophage f1 DNA by primed synthesis with DNA polymerase", J Mol Biol, 90, pp.315~333 (1974)
16. Sanger F, "A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase", J Mol Biol, 94, pp.441~448 (1975)
17. Lander ES, "Initial sequencing and analysis of the human genome", Nature, 409, pp.860~901 (2001)
18. Archer J, "Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism", PLoS One, 7, pp.e49602~ (2012)
19. Burghel GJ, "Towards a next-generation sequencing diagnostic service for tumour genotyping: A comparison of panels and platforms", Biomed Res Int, 2015, pp.478017~ (2015)
20. Mardis ER, "New strategies and emerging technologies for massively parallel sequencing: applications in medical research", Genome Med, 1, pp.40~ (2009)
21. Chang F, "Clinical application of amplicon-based next-generation sequencing in cancer", Cancer Genet, 206, pp.413~419 (2013)
22. Mardis ER, "Sequencing the AML genome, transcriptome, and epigenome", Sem Hematol, 51, pp.250~258 (2014)
23. Misyura M, "Comparison of next-generation sequencing panels and platforms for detection and verification of somatic tumor variants for clinical diagnostics", J Mol Diagn, 18, pp.842~850 (2016)
24. Fernandez-Cuesta L, "Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data", Genome Biol, 16, pp.7~ (2015)
25. Tilgner H, "Accurate identification and analysis of human mRNA isoforms using deep long read sequencing", G3 (Bethesda), 3, pp.387~397 (2013)
26. Niedringhaus TP, "Landscape of next-generation sequencing technologies", Anal Chem, 83, pp.4327~4341 (2011)
27. Dressman D, "Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations", Proc Natl Acad Sc USA, 100, pp.8817~8822 (2003)
28. Ansorge WJ, "Next-generation DNA sequencing techniques", N Biotechnol, 25, pp.195~203 (2009)
29. Metzker ML, "Sequencing technologies—the next generation", Nat Rev Genet, 11, pp.31~ (2010)
30. Margulies M, "Genome sequencing in microfabricated high-density picolitre reactors", Nature, 437, pp.376~ (2005)
31. Huse SM, "Accuracy and quality of massively parallel DNA pyrosequencing", Genome Biol, 8, pp.R143~ (2007)
32. Rothberg JM, "An integrated semiconductor device enabling non-optical genome sequencing", Nature, 475, pp.348~ (2011)
33. Liu L, "Comparison of next-generation sequencing systems", J Biomed Biotechnol, 2012, pp.251364~ (2012)
34. Mason CE, "Faster sequencers, larger datasets, new challenges", Genome Biol, 13, pp.314~ (2012)
35. Boland JF, "The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing", Human Genet, 132, pp.1153~1163 (2013)
36. Mehrotra M, "Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory", PLoS One, 12, pp.e0181968~ (2017)
37. Franzosa EA, "Sequencing and beyond: integrating molecular ‘omics’ for microbial community profiling", Nat Rev Microbiol, 13, pp.360~372 (2015)
38. Wang Z, "RNA-Seq: a revolutionary tool for transcriptomics", Nat Rev Genet, 10, pp.57~63 (2009)
39. Wilhelm BT, "RNA-Seq-quantitative measurement of expression through massively parallel RNA-sequencing", Methods, 48, pp.249~257 (2009)
40. Zhao S, "Comparison of RNASeq and microarray in transcriptome profiling of activated T cells", PLoS One, 9, pp.e78644~ (2014)
41. Zhou J, "Highthroughput metagenomic technologies for complex microbial community analysis: open and closed formats", mBio, 6, pp.e02288-14~ (2015)
42. Chen G, "Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target", Clin Cancer Res, 20, pp.5537~5546 (2014)
43. Hamid O, "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N Engl J Med, 369, pp.134~144 (2013)
44. Bentley DR, "Accurate whole human genome sequencing using reversible terminator chemistry", Nature, 456, pp.53~59 (2008)
45. Van Dijk EL, "Ten years of nextgeneration sequencing technology", Trends Genet, 30, pp.418~426 (2014)
46. Ravi RK, "MiSeq: A next generation sequencing platform for genomic analysis", Methods Mol Biol, 1706, pp.223~232 (2018)
47. Berlin K, "Assembling large genomes with single-molecule sequencing and localitysensitive hashing", Nature Biotechnol, 33, pp.623~630 (2015)
48. Eid J, "Real-time DNA sequencing from single polymerase molecules", Science, 323, pp.133~138 (2009)
49. Ferrarini M, "An evaluation of the PacBio RS platform for sequencing and de novo assembly of a chloroplast genome", BMC Genomics, 14, pp.670~ (2013)
50. van Dijk EL, "The third revolution in sequencing technology", Trends Genetics, 34, pp.666~681 (2018)
51. Travers KJ, "A flexible and efficient template format for circular consensus sequencing and SNP detection", Nucleic Acids Res, 38, pp.e159-e~ (2010)
52. Coupland P, "Direct sequencing of small genomes on the Pacific Biosciences RS without library preparation", Biotechniques, 53, pp.365~372 (2012)
53. Baker EAG, "SiLiCO: a simulator of long read sequencing in PacBio and Oxford Nanopore", BioRxiv 2016:076901, ~ (2016)
54. Korlach J, "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures", Proc Natl Acad Sci U S A, 105, pp.1176~1181 (2008)
55. Quail MA, "A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers", BMC Genomics, 13, pp.341~ (2012)
56. Brown SD, "Comparison of single-molecule sequencing and hybrid approaches for finishing the genome of Clostridium autoethanogenum and analysis of CRISPR systems in industrial relevant Clostridia", Biotechnol Biofuels, 7, pp.40~ (2014)
57. Weirather JL, "Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing", Nucleic Acids Res, 43, pp.e116~ (2015)
58. Bashir A, "A hybrid approach for the automated finishing of bacterial genomes", Nature Biotechnol, 30, pp.701~ (2012)
59. Koren S, "Hybrid error correction and de novo assembly of single-molecule sequencing reads", Nature Biotechnol, 30, pp.693~ (2012)
60. Miller DT, "Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies", Am J Hum Genet, 86, pp.749~764 (2010)
61. Yang Y, "Clinical whole-exome sequencing for the diagnosis of mendelian disorders", N Engl J Med, 369, pp.1502~1511 (2013)
62. Jacob HJ, "Genomics in clinical practice: lessons from the front lines", Sci Transl Med, 5, pp.194cm5~ (2013)
63. Jones MA, "Molecular diagnostic testing for congenital disorders of glycosylation (CDG): detection rate for single gene testing and next generation sequencing panel testing", Mol Genet Metab, 110, pp.78~85 (2013)
64. Vincent LM, "78: Multi-gene NGS panel yields high diagnostic rate of skeletal dysplasias detected by fetal ultrasound", Am J Obstet Gynecol, 218, pp.S57~S58 (2018)
65. Takahashi JS, "Forward and reverse genetic approaches to behavior in the mouse", Science, 264, pp.1724~1733 (1994)
66. Schulze TG, "Defining the phenotype in human genetic studies: forward genetics and reverse phenotyping", Hum Hered, 58, pp.131~138 (2004)
67. Boycott KM, "Rare-disease genetics in the era of next-generation sequencing: discovery to translation", Nat Rev Genet, 14, pp.681~691 (2013)
68. Arif B, "A novel OPA3 mutation revealed by exome sequencing: an example of reverse phenotyping", JAMA Neurol, 70, pp.783~787 (2013)
69. Urreizti R, "A de novo nonsense mutation in MAGEL2 in a patient initially diagnosed as Opitz-C: similarities between Schaaf-Yang and Opitz-C syndromes", Sci Rep, 7, pp.44138~ (2017)
70. Graziano C, "Syndromic intellectual disability: a new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant", Gene, 559, pp.144~148 (2015)
71. Liu H, "Atypi-cal fibrodysplasia ossificans progressiva diagnosed by whole-exome sequencing", Am J Med Genet A, 167, pp.1337~1341 (2015)
72. Worthey EA, "Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease", Genet Med, 13, pp.255~262 (2011)
73. Dillon OJ, "Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders", Eur J Hum Genet, 26, pp.644~651 (2018)
74. Consugar MB, "Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing", Genet Med, 17, pp.253~261 (2015)
75. Guan Q, "AUDIOME: a tiered exome sequencing-based comprehensive gene panel for the diagnosis of heterogeneous nonsyndromic sensorineural hearing loss", Genet Med, 20, pp.1600~1608 (2018)
76. Shashi V, "The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders", Genet Med, 16, pp.176~182 (2014)
77. Kalia SS, "Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics", Genet Med, 19, pp.249~255 (2017)
78. Retterer K, "Clinical application of whole-exome sequencing across clinical indications", Genet Med, 18, pp.696~704 (2016)
79. Tan TY, "Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions", JAMA Pediatr, 171, pp.855~862 (2017)
80. Yang Y, "Molecular findings among patients referred for clinical whole-exome sequencing", JAMA, 312, pp.1870~1879 (2014)
81. Farwell KD, "Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500unselected families with undiagnosed genetic conditions", Genet Med, 17, pp.578~586 (2015)
82. Xiao B, "Marked yield of reevaluating phenotype and exome", target sequencing data in 33 individuals with intellectual disabilities, 2018, pp.176, 107~115
83. Belkadi A, "Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants", Proc Natl Acad Sci U S A, 112, pp.5473~5478 (2015)
84. Stavropoulos DJ, "Whole genome sequencing expands diagnostic utility and improves clinical management in pediatric medicine", NPJ Genom Med, 1, pp.15012~ (2016)
85. Ellingford JM, "Whole genome sequencing increases molecular diagnostic yield compared with current diagnostic testing for inherited retinal disease", Ophthalmology, 123, pp.1143~1150 (2016)
86. Farnaes L, "Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization", NPJ Genom Med, 3, pp.10~ (2018)
87. Petrikin JE, "Rapid whole genome sequencing and precision neonatology", Semin Perinatol, 39, pp.623~631 (2015)
88. Schwarze K, "Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature", Genet Med, 20, pp.1122~1130 (2018)
89. Ghemlas I, "Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes", J Med Genet, 52, pp.575~584 (2015)
90. Meng L, "Use of exome sequencing for infants in intensive care units: ascertainment of severe single-gene disorders and effect on medical management", JAMA Pediatr, 171, pp.e173438~ (2017)
91. Surrey LF, "Clinical utility of custom-designed NGS panel testing in pediatric tumors", Genome Med, 11, pp.32~ (2019)
92. Miller TE, "Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma", J Clin Pathol, 71, pp.1108~1115 (2018)
93. 김혜진, "Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies", Annals of Laboratory Medicine, 39(6), pp.515~523 (2019), 대한진단검사의학회[DOI]
94. Chang F, "Development and clinical validation of a large fusion gene panel for pediatric cancers", J Mol Diagn, 21, pp.873~883 (2019)
95. Hutchins RJ, "Practical guidance to implementing quality management systems in public health laboratories performing nextgeneration sequencing: personnel, equipment, and process management (Phase 1)", J Clin Microbiol, 57, pp.e00261-19~ (2019)
96. Jennings LJ, "Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists", J Mol Diagn, 19, pp.341~365 (2017)
97. Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
98. Roy S, "Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists", J Mol Diagn, 20, pp.4~27 (2018)
99. Luthra R, "A targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors", J Mol Diagn, 19, pp.255~264 (2017)
100. Sakai K, "Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens", Cancer Sci, 110, pp.2044~2049 (2019)
101. Zehir A, "Mutational landscape of metastatic cancer revealed from prospective clini-cal sequencing of 10,000 patients", Nat Med, 23, pp.703~713 (2017)
102. Frampton GM, "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", Nat Biotechnol, 31, pp.1023~1031 (2013)
103. Cheng DT, "Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based nextgeneration sequencing clinical assay for solid tumor molecular oncology", J Mol Diagn, 17, pp.251~264 (2015)
104. Hodgson DR, "Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes", Br J Cancer, 119, pp.1401~1409 (2018)
105. Coccaro N, "Next-generation sequencing in acute lymphoblastic leukemia", Int J Mol Sci, 20, pp.2929~ (2019)
106. Papaemmanuil E, "Genomic classification and prognosis in acute myeloid leukemia", N Engl J Med, 374, pp.2209~2221 (2016)
107. Dufour A, "Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome", J Clin Oncol, 28, pp.570~577 (2010)
108. Sood R, "Role of RUNX1 in hematological malignancies", Blood, 129, pp.2070~2082 (2017)
109. Daver N, "Targeting FLT3 mutations in AML: review of current knowledge and evidence", Leukemia, 33, pp.299~312 (2019)
110. Medeiros BC, "Isocitrate dehydrogenase mutations in myeloid malignancies", Leukemia, 31, pp.272~281 (2017)
111. Ley TJ, "DNMT3A mutations in acute myeloid leukemia", N Engl J Med, 363, pp.2424~2433 (2010)
112. Delhommeau F, "Mutation in TET2 in myeloid cancers", N Engl J Med, 360, pp.2289~2301 (2009)
113. Weissmann S, "Landscape of TET2 mutations in acute myeloid leukemia", Leukemia, 26, pp.934~942 (2012)
114. Chou WC, "TET2mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics", Blood, 118, pp.3803~3810 (2011)
115. Itzykson R, "Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias", Leukemia, 25, pp.1147~1152 (2011)
116. Metzeler KH, "Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia", Blood, 128, pp.686~698 (2016)
117. Campo E, "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" (2017), IARC
118. Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
119. Cancer Genome Atlas Research Network, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)
120. D’Angelo SP, "Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas", J Clin Oncol, 29, pp.2066~2070 (2011)
121. Shaw AT, "ALK in lung cancer: past, present, and future", J Clin Oncol, 31, pp.1105~1111 (2013)
122. Shaw AT, "Crizotinib in ROS1-rearranged non-small-cell lung cancer", N Engl J Med, 371, pp.1963~1971 (2014)
123. Shaw AT, "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001", Ann Oncol, 30, pp.1121~1126 (2019)
124. Lindeman NI, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors:guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology", Arch Pathol Lab Med, 142, pp.p321~p346 (2018)
125. Yamamoto H, "An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine", Semin Oncol, 46, pp.261~270 (2019)
126. Zhao P, "Mismatch repair deficiency", microsatellite instability-high as a predictor for anti-PD-1, J Hematol Oncol, pp.2019, 12[DOI]
127. Marcus L, "FDA approval summary:pembrolizumab for the treatment of microsatellite instability-high solid tumors", Clin Cancer Res, 25, pp.3753~3758 (2019)
128. Mehrvarz Sarshekeh A, "Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer", Future Oncol, 14, pp.1869~1874 (2018)
129. Overman MJ, "Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient", microsatellite instability-high metastatic colorectal cancer, 2018, pp.36, 773~779
130. Cocco E, "NTRK fusion-positive cancers and TRK inhibitor therapy", Nat Rev Clin Oncol, 15, pp.731~747 (2018)
131. Hsiao SJ, "Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy", J Mol Diagn, 21, pp.553~571 (2019)
132. Ricciuti B, "Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence", Onco Targets Ther, 12, pp.3171~3179 (2019)
133. Drilon A, "Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children", N Engl J Med, 378, pp.731~739 (2018)
134. Doebele RC, "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.271~282 (2020)
135. Drilon A, "Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.261~270 (2020)
136. Chan TA, "Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic", Ann Oncol, 30, pp.44~56 (2019)
137. Steuer CE, "Tumor mutation burden: leading immunotherapy to the era of precision medicine?", J Clin Oncol, 36, pp.631~632 (2018)
138. Cunanan KM, "An efficient basket trial design", Stat Med, 36, pp.1568~1579 (2017)
139. Strzebonska K, "Umbrella and basket trials in oncology:ethical challenges", BMC Med Ethics, 20, pp.58~ (2019)
140. McNeil C, "NCI-MATCH launch highlights new trial design in precisionmedicine era", J Natl Cancer Inst, 107, pp.djv193~ (2015)
141. Luskin MR, "Targeting minimal residual disease: a path to cure?", Nat Rev Cancer, 18, pp.255~263 (2018)
142. Cilloni D, "Digital PCR in myeloid malignancies: ready to replace quantitative PCR?", Int J Mol Sci, 20, pp.2249~ (2019)
143. Romano A, "Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives", Front Oncol, 9, pp.699~ (2019)
144. Wu D, "Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH", Clin Cancer Res, 20, pp.4540~4548 (2014)
145. Wood B, "Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL", Blood, 131, pp.1350~1359 (2018)
146. Berger MF, "The emerging clinical relevance of genomics in cancer medicine", Nat Rev Clin Oncol, 15, pp.353~365 (2018)
147. Chin RI, "Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)", Mol Diagn Ther, 23, pp.311~331 (2019)
148. Rossi G, "Promises and pitfalls of using liquid biopsy for precision medicine", Cancer Res, 79, pp.2798~2804 (2019)
149. Heitzer E, "Current and future perspectives of liquid biopsies in genomics-driven oncology", Nat Rev Genet, 20, pp.71~88 (2019)
150. Bryan C. Ulrich, "Cell-Free DNA in Oncology: Gearing up for Clinic", Annals of Laboratory Medicine, 38(1), pp.1~8 (2018), 대한진단검사의학회
151. Brown P, "The Cobas EGFR Mutation Test v2 assay", Future Oncol, 12, pp.451~452 (2016)
152. Clark TA, "Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA", J Mol Diagn, 20, pp.686~702 (2018)
153. Aravanis AM, "Next-generation sequencing of circulating tumor DNA for early cancer detection", Cell, 168, pp.571~574 (2017)
154. Wang Y, "Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers", Sci Transl Med, 10, pp.eaap8793~ (2018)
155. Cohen JD, "Detection and localization of surgically resectable cancers with a multi-analyte blood test", Science, 359, pp.926~930 (2018)
156. Merker JD, "Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review", J Clin Oncol, 36, pp.1631~1641 (2018)
157. Razavi P, "High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants", Nat Med, 25, pp.1928~1937 (2019)
158. Lozano R, "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2095~2128 (2010)
159. Ewig S, "Factors associated with unknown aetiology in patients with community-acquired pneumonia", Eur Respir J, 20, pp.1254~1262 (2002)
160. Bleeker-Rovers CP, "A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol", Medicine (Baltimore), 86, pp.26~38 (2007)
161. Karkhane M, "Annual antibiotic related economic burden of healthcare associated infections; a cross-sectional population based study", Iran J Pharm Res, 15, pp.605~610 (2016)
162. Weng QY, "Costs and consequences associated with misdiagnosed lower extremity cellulitis", JAMA Dermatol, 153, pp.141~146 (2017)
163. Amexo M, "Malaria misdiagnosis: effects on the poor and vulnerable", Lancet, 364, pp.1896~1898 (2004)
164. Kapur V, "Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing", Arch Pathol Lab Med, 119, pp.131~138 (1995)
165. Tang YW, "Comparison of phenotypic and genotypic techniques for identification of unusual aerobic pathogenic gram-negative bacilli", J Clin Microbiol, 36, pp.3674~3679 (1998)
166. Allicock OM, "BacCapSeq: a platform for diagnosis and characterization of bacterial infections", mBio, 9, pp.e02007~e02018 (2018)
167. Briese T, "Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis", mBio, 6, pp.e01491-15~ (2015)
168. Buss SN, "Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis", J Clin Microbiol, 53, pp.915~925 (2015)
169. Babady NE, "The FilmArray® respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens", Expert Rev Mol Diagn, 13, pp.779~788 (2013)
170. Leber AL, "Multicenter evaluation of biofire filmarray meningitis", encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens, 2016, pp.54, 2251~2261
171. CRyPTIC Consortium and the 100, "Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing", N Engl J Med, 379, pp.1403~1415 (2018)
172. Nimmo C, "Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum", Int J Infect Dis, 62, pp.44~46 (2017)
173. Quan TP, "Evaluation of whole-genome sequencing for mycobacterial species identification and drug susceptibility testing in a clinical setting: a largescale prospective assessment of performance against line probe assays and phenotyping", J Clin Microbiol, 56, pp.e01480-17~ (2018)
174. Ellington MJ, "The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee", Clin Microbiol Infect, 23, pp.2~22 (2017)
175. Burnham P, "Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract", Nat Commun, 9, pp.2412~ (2018)
176. Doan T, "Metagenomic DNA sequencing for the diagnosis of intraocular infections", Ophthalmology, 124, pp.1247~1248 (2017)
177. Graf EH, "Unbiased detection of respiratory viruses by use of RNA sequencingbased metagenomics: a systematic comparison to a commercial PCR panel", J Clin Microbiol, 54, pp.1000~1007 (2016)
178. Mongkolrattanothai K, "Neurobrucellosis: unexpected answer from metagenomic next-generation sequencing", J Pediatric Infect Dis Soc, 6, pp.393~398 (2017)
179. Simner PJ, "Development and optimization of metagenomic next-generation sequencing methods for cerebrospinal fluid diagnostics", J Clin Microbiol, 56, pp.e00472-18~ (2018)
180. Schlaberg R, "Validation of metagenomic next-generation sequencing tests for universal pathogen detection", Arch Pathol Lab Med, 141, pp.776~786 (2017)
181. Miller S, "Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid", Genome Res, 29, pp.831~842 (2019)
182. Hasan MR, "Depletion of human DNA in spiked clinical specimens for improvement of sensitivity of pathogen detection by next-generation sequencing", J Clin Microbiol, 54, pp.919~927 (2016)
183. Blauwkamp TA, "Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease", Nat Microbiol, 4, pp.663~674 (2019)
184. Thoendel M, "Impact of contaminating DNA in whole-genome amplification kits used for metagenomic shotgun sequencing for infection diagnosis", J Clin Microbiol, 55, pp.1789~1801 (2017)
185. Naccache SN, "The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns", J Virol, 87, pp.11966~11977 (2013)
186. de Goffau MC, "Recognizing the reagent microbiome", Nat Microbiol, 3, pp.851~853 (2018)
187. Quick J, "Real-time, portable genome sequencing for Ebola surveillance", Nature, 530, pp.228~232 (2016)
188. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
189. Sammons JS, "Outbreak of adenovirus in a neonatal intensive care unit: critical importance of equipment cleaning during inpatient ophthalmologic examinations", Ophthalmology, 126, pp.137~143 (2019)
190. Etienne KA, "Whole-genome sequencing to determine origin of multinational outbreak of Sarocladium kiliense bloodstream infections", Emerg Infect Dis, 22, pp.476~481 (2016)
191. Snitkin ES, "Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing", Sci Transl Med, 4, pp.148ra116~ (2012)
192. Paterson GK, "Capturing the cloud of diversity reveals complexity and heterogeneity of MRSA carriage, infection and transmission", Nat Commun, 6, pp.6560~ (2015)
193. Lockhart SR, "Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses", Clin Infect Dis, 64, pp.134~140 (2017)
194. Hoffmann M, "Tracing origins of the Salmonella Bareilly strain causing a food-borne outbreak in the United States", J Infect Dis, 213, pp.502~508 (2016)
195. Jackson BR, "Implementation of nationwide real-time whole-genome sequencing to enhance listeriosis outbreak detection and investigation", Clin Infect Dis, 63, pp.380~386 (2016)
196. Moura A, "Real-time whole-genome sequencing for surveillance of Listeria monocytogenes, France", Emerg Infect Dis, 23, pp.1462~1470 (2017)
197. Shepard SS, "Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler", BMC Genomics, 17, pp.708~ (2016)
198. Gwinn M, "Integrating advanced molecular technologies into public health", J Clin Microbiol, 55, pp.703~714 (2017)
199. Thoendel MJ, "Identification of prosthetic joint infection pathogens using a shotgun metagenomics approach", Clin Infect Dis, 67, pp.1333~1338 (2018)
200. Ivy MI, "Direct detection and identification of prosthetic joint infection pathogens in synovial fluid by metagenomic shotgun sequencing", J Clin Microbiol, 56, pp.e00402~e00418 (2018)
201. Zhou Y, "Metagenomic approach for identification of the pathogens associated with diarrhea in stool specimens", J Clin Microbiol, 54, pp.368~375 (2016)
202. Li Z, "Identifying corneal infections in formalin-fixed specimens using next generation sequencing", Invest Ophthalmol Vis Sci, 59, pp.280~288 (2018)
203. Wilson MR, "Chronic meningitis investigated via metagenomic nextgeneration sequencing", JAMA Neurol, 75, pp.947~955 (2018)
204. Grumaz S, "Next-generation sequencing diagnostics of bacteremia in septic patients", Genome Med, 8, pp.73~ (2016)
205. Long Y, "Diagnosis of sepsis with ell-free DNA by next-generation sequencing technology in ICU patients", Arch Med Res, 47, pp.365~371 (2016)
206. Wylie KM, "Sequence analysis of the human virome in febrile and afebrile children", PLoS One, 7, pp.e27735~ (2012)
207. Wilson MR, "Actionable diagnosis of neuroleptospirosis by next-generation sequencing", N Engl J Med, 370, pp.2408~2417 (2014)
208. Hoffmann B, "A variegated squirrel bornavirus associated with fatal human encephalitis", N Engl J Med, 373, pp.154~162 (2015)
209. Greninger AL, "Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing", Genome Med, 7, pp.113~ (2015)
210. Wilson MR, "Diagnosing Balamuthia mandrillaris encephalitis with metagenomic deep sequencing", Ann Neurol, 78, pp.722~730 (2015)
211. Schmidt K, "Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing", J Antimicrob Chemother, 72, pp.104~114 (2017)
212. Lemon JK, "Rapid nanopore sequencing of plasmids and resistance gene detection in clinical isolates", J Clin Microbiol, 55, pp.3530~3543 (2017)
213. Tamma PD, "Applying rapid whole-genome sequencing to predict phenotypic antimicrobial susceptibility testing results among carbapenem-resistant Klebsiella pneumoniae clinical isolates", Antimicrob Agents Chemother, 63, pp.e01923-18~ (2019)
214. Tzou PL, "Comparison of an in vitro diagnostic next-generation sequencing assay with Sanger sequencing for HIV-1 genotypic resistance testing", J Clin Microbiol, 56, pp.e00105~e00118 (2018)
215. Tyson GH, "WGS accurately predicts antimicrobial resistance in Escherichia coli", J Antimicrob Chemother, 70, pp.2763~2769 (2015)
216. Shea J, "Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State", J Clin Microbiol, 55, pp.1871~1882 (2017)
217. Jaillard M, "Correlation between phenotypic antibiotic susceptibility and the resistome in Pseudomonas aeruginosa", Int J Antimicrob Agents, 50, pp.210~218 (2017)
218. Sabat AJ, "Targeted next-generation sequencing of the 16S-23S rRNA region for culture-independent bacterial identification - increased discrimination of closely related species", Sci Rep, 7, pp.3434~ (2017)
219. Salipante SJ, "Coinfection of Fusobacterium nucleatum and Actinomyces israelii in mastoiditis diagnosed by next-generation DNA sequencing", J Clin Microbiol, 52, pp.1789~1792 (2014)
220. Sardi SI, "Coinfections of Zika and chikungunya viruses in Bahia, Brazil, identified by metagenomic next-generation sequencing", J Clin Microbiol, 54, pp.2348~2353 (2016)
221. Miao Q, "Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice", Clin Infect Dis, 67(S2), pp.S231~S240 (2018)
222. Langelier C, "Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults", Proc Natl Acad Sci U S A, 115, pp.E12353~E12362 (2018)
223. Bal A, "Metagenomic next-generation sequencing reveals individual composition and dynamics of anelloviruses during autologous stem cell transplant recipient management", Viruses, 10, pp.633~ (2018)
224. De Vlaminck I, "Temporal response of the human virome to immunosuppression and antiviral therapy", Cell, 155, pp.1178~1187 (2013)
225. De Vlaminck I, "Noninvasive monitoring of infection and rejection after lung transplantation", Proc Natl Acad Sci U S A, 112, pp.13336~13341 (2015)
226. Zhao J, "Decade-long bacterial community dynamics in cystic fibrosis airways", Proc Natl Acad Sci U S A, 109, pp.5809~5814 (2012)
227. Morgan XC, "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment", Genome Biol, 13, pp.R79~ (2012)
228. van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)
229. Petersen BS, "Opportunities and challenges of whole-genome and -exome sequencing", BMC Genet, 18, pp.14~ (2017)
230. 김영은, "Challenges and Considerations in Sequence Variant Interpretation for Mendelian Disorders", Annals of Laboratory Medicine, 39(5), pp.421~429 (2019), 대한진단검사의학회[DOI]
231. Chen G, "Single-cell RNA-seq technologies and related computational data analysis", Front Genet, 10, pp.317~ (2019)
232. Schrader KA, "Germline variants in targeted tumor sequencing using matched normal DNA", JAMA Oncol, 2, pp.104~111 (2016)
233. Akkari Y, "Implementation of cancer next-generation sequencing testing in a community hospital", Cold Spring Harb Mol Case Stud, 5, pp.a003707~ (2019)

관련 논문AI추천